Pneumococcal Vaccines Show Moderate Immunogenicity, Strong Safety in Children With Cancer

A study presented at IDWeek 2026 indicates that pneumococcal vaccines provide moderate protection for children with cancer, though efficacy is significantly reduced during chemotherapy. Researchers suggest that timing and dosage are critical for maintaining immunity in immunocompromised patients.
Why it matters
Provides essential clinical guidance for pediatric oncology care to improve infection prevention strategies.
Pneumococcal vaccines produced moderate immune responses and were well tolerated in children with cancer, but protection was weaker during active chemotherapy and faded within a year after treatment, according to a systematic review and meta-analysis presented at IDWeek 2026 in Washington, DC.1
Children with cancer face a 20- to 100-fold higher risk of invasive pneumococcal disease (IPD) than other children because of immunosuppression from both malignancy and chemotherapy. In a Brazilian pediatric oncology cohort, IPD incidence reached about 311.21 cases per 100,000 patient-years, with a mortality rate of 7.8%. Severe neutropenia was the only independent risk factor identified. The CDC recommends risk-based pneumococcal vaccination for children with immunocompromising conditions, including leukemia, lymphoma, and other malignancies, but optimal timing relative to chemotherapy remains unclear.1-3
Review Included 18 Studies and 2847 Children
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in